ASX:MSBBiotechs
Assessing Mesoblast’s Valuation After FDA Clears New Ryoncil Trial In Duchenne Muscular Dystrophy
Mesoblast (ASX:MSB) is back in focus after the US Food and Drug Administration granted investigational new drug clearance for a registrational trial of Ryoncil in Duchenne muscular dystrophy, a high-need pediatric indication.
See our latest analysis for Mesoblast.
Despite the FDA news and Ryoncil sales updates, recent trading has been choppy, with a 90 day share price return decline of 33.88%, even as the 3 year total shareholder return stands at 119.59%. At A$2.03, recent moves suggest...